Clinical trials
Low Risk clinical trials
Below are recruiting low risk clinical trials, each written for real people, not researchers. We’re tracking 169 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07376837Recruiting
Radiofrequency ablation for small low-risk thyroid cancer
This study tests whether radiofrequency ablation (a heat-based treatment applied through the skin) can safely and effectively cure small, low-risk papillary thyroid cancers. It is designed for people whose tumors are small, have not spread, and who either cannot have surgery or prefer not to.
Toronto, OntarioAges 18 years+ - NCT07328854RecruitingPhase 3
Lower versus standard radiation in stage II nasopharyngeal cancer
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
Hefei, AnhuiAges 18–75 - NCT07330323Recruiting
Custom skin cancer aftercare report study
This trial tests a personalized aftercare report for people with low-risk skin cancer. It aims to see if this report can improve follow-up care.
Leuven, Vlaams-BrabantAges 18–80 - NCT07260526Recruiting
Chemo and radiation for low rectal cancer, aiming to avoid surgery
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
Chengdu, SichuanAges 18–80 - NCT07265518Recruiting
Starting labor at home with a balloon catheter
This trial tests if you can safely start labor at home using a soft balloon device, instead of staying in the hospital. If you have a low-risk pregnancy and need to be induced, this approach may allow you to spend more time comfortably at home.
Nantes, Loire AtlantiqueAges 18 years+ - NCT07231627Recruiting
Using AI to improve prostate cancer detection from MRI
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
Little Rock, ArkansasAges 40 years+ - NCT06929650Recruiting
Radiofrequency ablation for low-risk thyroid cancer
This trial tests a procedure called radiofrequency ablation to treat small, low-risk thyroid cancer. If you have a small nodule (2 cm or less) that is confirmed as cancer or suspicious for cancer (Bethesda 5/6), this treatment may be an option instead of surgery.
Toronto, OntarioAges 18–100 - NCT07192016RecruitingPhase 4
MRI study of triple inhaler for COPD with breathlessness
This study uses a special MRI scan to see how well a single triple inhaler works for people with COPD who have moderate to severe shortness of breath or feel their health is not good. It compares two groups: those with a low risk of flare-ups and those with a high risk, to find out if the treatment helps both groups.
London, OntarioAges 50–85 - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT06866041Recruiting
Prostate cancer markers and imaging for low-risk patients on active surveillance
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Milan, ItalyAges 45–80 - NCT07082530Recruiting
Labor induction at 39 weeks for low-risk pregnant women in China
This study compares inducing labor at 39 weeks to waiting for natural labor in women with low-risk pregnancies. It aims to see if planned induction leads to better outcomes for mothers and babies.
Hangzhou, ZhejiangAges 18 years+ - NCT07019636Recruiting
Direct extubation vs. extubation after a breathing trial
This study compares two ways of removing the breathing tube (extubation) in patients who are ready to breathe on their own: taking the tube out right away, or doing a trial of breathing without the machine first. It is for people who are at low risk of needing the tube put back in.
ParisAges 18–65 - NCT06209099Recruiting
Organ preservation first for low-risk rectal cancer
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
Beijing, Haidian DistrictAges 18–85 - NCT06924151Recruiting
Surgery for Aortic Valve in Low Risk Patients
This trial tests if surgery to replace your aortic valve is safe and effective for people with severe aortic stenosis who are at low risk for complications. It compares surgery to another procedure to see which works best.
Matsudo, ChibaAges Any age - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Los Angeles, CaliforniaAges 18 years+ - NCT06882057RecruitingPhase 2/Phase 3
Treatment for newly diagnosed low-risk pediatric B-ALL
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hefei, AnhuiAges 1–18 - NCT06847867RecruitingPhase 2
Testing momelotinib for low-risk myelodysplastic syndrome
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Goodyear, ArizonaAges 18 years+ - NCT06803147Recruiting
Stopping Surveillance for Low-Risk Barrett's Esophagus
This study is testing whether it's safe to stop regular surveillance endoscopies for people with low-risk Barrett's esophagus. If you have a short Barrett's segment without any dysplasia, you may be able to avoid future procedures.
AmsterdamAges Any age - NCT06787339RecruitingPhase 2
Capecitabine for low-risk triple negative breast cancer
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06773871Recruiting
Exercise study for low-risk myeloid cancers and precursor conditions
This trial tests whether exercise is safe and feasible for people with low-risk myeloid cancers or certain bone marrow conditions. It aims to see if a supervised exercise program can be done without problems.
Copenhagen, DenmarkAges 18 years+ - NCT06727864RecruitingPhase 3
Short-course treatment for low-risk active lung TB
This trial tests a shorter treatment course (instead of the standard 6 months) for people with low-risk active TB in the lungs. It aims to see if the shorter regimen works just as well and has fewer side effects.
New Taipei City, BangiaoAges 20–99 - NCT06689956Recruiting
Observation after surgery for low-risk endometrial cancer with tiny lymph node findings
This study looks at women with low-risk endometrial cancer who had tiny amounts of cancer cells found in their sentinel lymph nodes during surgery. Doctors want to see if it's safe to avoid additional treatments like chemotherapy or radiation.
Rochester, MinnesotaAges Any age - NCT06671691Enrolling by invitationPhase 1
Single-dose radiation for low-risk breast cancer
This trial tests a single, high-precision dose of radiation to the tumor instead of standard surgery or multiple radiation sessions. It is for women with a small, low-risk breast cancer who cannot or choose not to have surgery.
Palma, Balearic IslandsAges Any age - NCT06649058RecruitingPhase 2
Study on combining drugs and radiation for brain metastases
This trial is for people with cancer that has spread to the brain (brain metastases). It tests a new approach where you start a systemic therapy (drugs that travel through your body) and later add focused radiation to the brain tumors, instead of treating them right away. The goal is to see if this sequence works well and avoids unnecessary side effects.
Houston, TexasAges 18 years+
Hear when a new Low Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for low risk?
- Yes. Clin2 currently lists 169 recruiting low risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a low risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a low risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.